Comparison of sensory attributes and immediate efficacy of intranasal ciclesonide and fluticasone propionate in allergic rhinitis: A randomized controlled trial

被引:5
作者
Varshney, Jitendra [3 ]
Varshney, Himanshu [2 ]
Dutta, Sumanta Kumar [4 ]
Hazra, Avijit [1 ]
机构
[1] Inst Postgrad Med Educ & Res IPGME & R, Dept Pharmacol, Kolkata, India
[2] Inst Postgrad Med Educ & Res IPGME & R, Dept Otorhinolaryngol, Kolkata, India
[3] SGRRITS, Dept Clin Pharm, Dehra Dun, Uttarakhand, India
[4] Calcutta Natl Med Coll & Hosp, Dept Otorhinolaryngol, Kolkata, W Bengal, India
关键词
Allergic rhinitis; ciclesonide; fluticasone propionate; intranasal corticosteroid; PATIENT PREFERENCE; NASAL SPRAY; CORTICOSTEROIDS; SAFETY; MULTICENTER; CROSSOVER; FUROATE; BLIND;
D O I
10.4103/0253-7613.100365
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Intranasal corticosteroids (INCs) are the most effective modality for treating allergic rhinitis and their sensory attributes are important in patient compliance. This study aimed to compare the sensory attributes (scent, immediate taste, aftertaste, run down to throat, nose run off, soothing feel, nasal irritation, and urge to sneeze) and immediate response to the new intranasal steroid, ciclesonide (CIC), with fluticasone propionate (FLP) in allergic rhinitis. Materials and Methods: A randomized, double blind, single dose, crossover study was done with 74 patients presenting with acute allergic rhinitis. Eligible subjects were randomized in 1:1 ratio to one of the two treatment sequences - CIC followed by FLP or vice versa. Sensory attributes were assessed using a questionnaire to score each item on a seven-point Likert scale, immediately and 2 min after dosing. Total nasal symptom score (TNSS) was calculated to evaluate immediate efficacy 10 min after first drug administration. Overall preference was recorded 10 min after the second drug administration. Patients were queried about treatment emergent adverse events following study drug administration and also 24 h later over the phone. Results: Patients (58 males; pooled median age 32 years [Interquartile range, IQR, 25-41]; pooled median symptom duration 24 months [IQR 12-72]) preferred FLP over CIC nasal spray overall (55.41 vs. 25.68, P = 0.007) and also with respect to attributes of scent, soothing feel, and nasal irritation. There was no statistically significant difference in immediate efficacy. Two patients reported mild headache following CIC first, while three felt mild headache, one dizziness, and one nasal congestion following FLP first administration. There were no delayed adverse events. Conclusions: There was no difference in immediate outcome following use of either of the two INCs. FLP was preferred over CIC with respect to scent, soothing feel and nasal irritation, and also overall. There were no significant adverse events.
引用
收藏
页码:550 / 554
页数:5
相关论文
共 16 条
  • [1] Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)
    Bousquet, J.
    van Cauwenberge, P.
    Khaled, N. Ait
    Bachert, C.
    Baena-Cagnani, C. E.
    Bouchard, J.
    Bunnag, C.
    Canonica, G. W.
    Carlsen, K. -H.
    Chen, Y. -Z.
    Cruz, A. A.
    Custovic, A.
    Demoly, P.
    Dubakiene, R.
    Durham, S.
    Fokkens, W.
    Howarth, P.
    Kemp, J.
    Kowalski, M. L.
    Kvedariene, V.
    Lipworth, B.
    Lockey, R.
    Lund, V.
    Mavale-Manuel, S.
    Meltzer, E. O.
    Mullol, J.
    Naclerio, R.
    Nekam, K.
    Ohta, K.
    Papadopoulos, N.
    Passalacqua, G.
    Pawankar, R.
    Popov, T.
    Potter, P.
    Price, D.
    Scadding, G.
    Simons, F. E. R.
    Spicak, V.
    Valovirta, E.
    Wang, D. -Y.
    Yawn, B.
    Yusuf, O.
    [J]. ALLERGY, 2006, 61 (09) : 1086 - 1096
  • [2] Once-daily administration of intranasal corticosteroids for allergic rhinitis: A comparative review of efficacy, safety, patient preference, and cost
    Herman, Howard
    [J]. AMERICAN JOURNAL OF RHINOLOGY, 2007, 21 (01): : 70 - 79
  • [3] Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis
    Khanna, P
    Shah, A
    [J]. AMERICAN JOURNAL OF RHINOLOGY, 2005, 19 (03): : 316 - 321
  • [4] Willingness to pay for sensory attributes of intranasal corticosteroids among patients with allergic rhinitis
    Mahadevia, P
    Shah, S
    Mannix, S
    Brewster-Jordan, J
    Kleinman, L
    Leibman, C
    O'Dowd, L
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2006, 12 (02): : 143 - 151
  • [5] Time Interval and the Factors Associated with the Development of Asthma in Patients with Allergic Rhinitis
    Mahesh, P. A.
    Vedanthan, P. K.
    Holla, Amrutha D.
    Jayaraj, B. S.
    Prabhakar, A. K.
    [J]. LUNG, 2009, 187 (06) : 393 - 400
  • [6] Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: A randomized, multicenter, double-blind, single-dose, crossover study
    Meltzer, Eli O.
    Stahlman, Jon E.
    Leflein, Jeffrey
    Meltzer, Steven
    Lim, Junghee
    Dalal, Anand A.
    Prillaman, Barbara A.
    Philpot, Edward E.
    [J]. CLINICAL THERAPEUTICS, 2008, 30 (02) : 271 - 279
  • [7] Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis
    Meltzer, Eli O.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (01) : 12 - 21
  • [8] Meltzer Eli O, 2005, Treat Respir Med, V4, P289, DOI 10.2165/00151829-200504040-00007
  • [9] Development of questionnaires to measure patient preferences for intranasal corticosteroids in patients with allergic rhinitis
    Meltzer, EO
    Hadley, J
    Blaiss, M
    Benninger, M
    Kimel, M
    Kleinman, L
    Dupclay, L
    Garcia, J
    Leahy, M
    Georges, G
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2005, 132 (02) : 197 - 207
  • [10] Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis
    Nave, R
    Wingertzahn, MA
    Brookman, S
    Kaida, S
    Matsunaga, T
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (04) : 461 - 467